These data support less restrictive clinical trial eligibility criteria for those with metastatic NSCLC. This is especially true regarding both targeted therapy and immunotherapy treatment regimens.
Sunil Tulpule, MD
Advertisement
Articles by Sunil Tulpule, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Nivolumab/AVD in Untreated Hodgkin Lymphoma
2
Comparison of the 3 Most Commonly Used Modified PD-1 Inhibitors Plus Chemotherapy in Inoperable Wild-Type Non–Small Cell Lung Cancer
3
NCCN Guidelines Add Novel Therapeutics to First-Line TNBC Armamentarium
4
Liquid Biopsies, Blood-Based MCED Tests for Detecting CRC in Young Patients
5